Metabolic syndrome in Sjogren's syndrome patients: a relevant concern for clinical monitoring

Author(s)

Augusto, Kristopherson Lustosa ^[1] ; Bonfa, Eloisa ^[1] ; Rodrigues Pereira, Rosa Maria ^[1] ; Bueno, Cleonice ^[1] ; Leon, Elaine Pires ^[1] ; Trindade Viana, Vilma Santos ^[1] ; Pasoto, Sandra Gofinet ^{[1, 2]}

Affiliation

^[1] Univ Sao Paulo, Fac Med, Hosp Clin, Div Rheumatol, Sao Paulo - Brazil

^[2] Univ Sao Paulo, Fac Med, Disciplina Reumatol, Av Dr Arnaldo 455, 3 Andar, Sala 3192, BR-01246903 Sao Paulo, SP - Brazil

• Document type: Journal article
• Source: CLINICAL RHEUMATOLOGY; v. 35, n. 3, p. 639-647, MAR 2016.
• Web of Science Citations: 9

Abstract

Metabolic syndrome (MetS) has been described in autoimmune diseases. However, there are scarce data about MetS and adipocytokine profile in primary Sjogren's syndrome (pSS). Seventy-one female pSS patients (American-European Consensus Group Criteria, 2002) aged 18-65 years and 71 age-, race-matched control women were enrolled in this case-control study. Clinical data were collected by a standardized protocol. Blood levels of glucose, cholesterol, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), triglycerides, interleukin-1beta (IL-1beta)/IL-6, B-cell activating factor (BAFF), insulin, and leptin/adiponectin/visfatin/resistin were determined. Patients and controls were comparable regarding body mass index (BMI), smoking, sedentariness, and menopause (p > 0.05). MetS (39.4 vs. 16.9 %, p = 0.005), hypertension (p = 0.004), and dyslipidemia (p = 0.002) were more frequent in patients than controls. IL-1beta, IL-6, BAFF, resistin, and adiponectin levels were higher in patients than controls (p < 0.05). pSS patients with MetS (n = 28) had higher BMI, waist circumference, cholesterol, LDL-C, triglycerides, insulin, leptin and HOMA-IR values, and greater hypertension and diabetes rates than pSS patients without MetS (n = 43) (p < 0.05). Current and/or previous prednisone use (75.0 vs. 62.8 %, p = 0.313), current (3.0 +/- 4.5 vs. 1.6 +/- 3.2 mg/day, p = 0.299), and cumulative prednisone doses (p = 0.495) were similar in both groups. Otherwise, IL-1beta level was higher in MetS patients than in non-MetS patients (p = 0.012), and this finding was confirmed (p = 0.048) by multivariate analysis with adjustments for age, ethnicity, prednisone use, current and cumulative prednisone doses, and duration of use. We identified high MetS frequency and abnormal adipocytokine profile in pSS. The association of MetS with elevated IL-1beta level suggests that inflammation plays an important role in its pathogenesis. (AU)

• FAPESP's process: 11/10490-0 - Osteoporosis and metabolic syndrome in patients with primary Sjögren's syndrome
• Grantee: Eloisa Silva Dutra de Oliveira Bonfá
• Support Opportunities: Regular Research Grants